VIOLIN: Vaccine Investigation and Online Information Network

Vaccine Detail

Ipilimumab

Vaccine Information

Vaccine Name: Ipilimumab
Target Pathogen: Cancer
Target Disease: Cancer
Vaccine Ontology ID: VO_0007626
Type: Monoclonal Antibody
Status: Research
Antigen: cytotoxic T-lymphocyte antigen-4 (CTLA4)
Immunization Route: Intramuscular injection (i.m.)
Description: These findings support the hypothesis that ipilimumab-treated patients with advanced melanoma have similar outcomes regardless of their HLA-A*0201 status. This vaccine may not be the best use due to its adverse affects on the patient's health (Wolchok et al., 2010).

Host Response

References

Wolchok et al., 2010: Wolchok JD, Weber JS, Hamid O, LebbÃ© C, Maio M, Schadendorf D, de Pril V, Heller K, Chen TT, Ibrahim R, Hoos A, O'Day SJ. Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trials. Cancer immunity. 2010; 10; 9. [PubMed: 20957980].